Sei Yoshida

587 total citations
22 papers, 372 citations indexed

About

Sei Yoshida is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Sei Yoshida has authored 22 papers receiving a total of 372 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Organic Chemistry and 5 papers in Oncology. Recurrent topics in Sei Yoshida's work include Melanoma and MAPK Pathways (6 papers), Synthesis and biological activity (5 papers) and Computational Drug Discovery Methods (4 papers). Sei Yoshida is often cited by papers focused on Melanoma and MAPK Pathways (6 papers), Synthesis and biological activity (5 papers) and Computational Drug Discovery Methods (4 papers). Sei Yoshida collaborates with scholars based in Japan, United States and Cyprus. Sei Yoshida's co-authors include Tomoyasu Ishikawa, Takeo Arita, Masanori Okaniwa, Akito Nakamura, Masato Yabuki, Elizabeth Carideo, Katherine Galvin, Kenichiro Naito, Jill Donelan and Kiyoshi Koshida and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Biochemical and Biophysical Research Communications.

In The Last Decade

Sei Yoshida

22 papers receiving 367 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sei Yoshida Japan	11	273	112	81	73	52	22	372
Amy M. Delaney United States	7	292 1.1×	90 0.8×	83 1.0×	33 0.5×	54 1.0×	8	441
Jörn Weisner Germany	11	278 1.0×	63 0.6×	145 1.8×	34 0.5×	31 0.6×	20	426
Min‐Wu Chao Taiwan	15	364 1.3×	149 1.3×	86 1.1×	46 0.6×	31 0.6×	26	492
Brian Zifcak United States	7	431 1.6×	136 1.2×	125 1.5×	51 0.7×	31 0.6×	10	570
Ahmed S.A. Mady United States	9	341 1.2×	114 1.0×	81 1.0×	32 0.4×	25 0.5×	13	444
Da-Qiang Li China	11	334 1.2×	139 1.2×	44 0.5×	41 0.6×	45 0.9×	19	425
Chon Lai United States	6	286 1.0×	72 0.6×	57 0.7×	30 0.4×	41 0.8×	10	364
Laurie S. Kane-Carson United States	6	326 1.2×	177 1.6×	135 1.7×	102 1.4×	67 1.3×	8	481
Rosemary Burke United Kingdom	13	404 1.5×	112 1.0×	93 1.1×	54 0.7×	15 0.3×	24	579
Shengyong Yang China	13	187 0.7×	103 0.9×	73 0.9×	22 0.3×	20 0.4×	18	356

Countries citing papers authored by Sei Yoshida

Since Specialization

Citations

This map shows the geographic impact of Sei Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sei Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sei Yoshida more than expected).

Fields of papers citing papers by Sei Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sei Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sei Yoshida. The network helps show where Sei Yoshida may publish in the future.

Co-authorship network of co-authors of Sei Yoshida

This figure shows the co-authorship network connecting the top 25 collaborators of Sei Yoshida. A scholar is included among the top collaborators of Sei Yoshida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sei Yoshida. Sei Yoshida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mpekris, Fotios, Myrofora Panagi, Christina Michael, et al.. (2022). Translational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment. Journal of Controlled Release. 353. 956–964. 15 indexed citations

Matsumoto, Hiroki, Fukiko Hihara, Atsuo Waki, et al.. (2022). Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET. Pharmaceutics. 14(9). 1928–1928. 4 indexed citations

Matsumoto, Hiroki, Tadashi Watabe, Fukiko Hihara, et al.. (2021). Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates. Pharmaceuticals. 14(10). 950–950. 4 indexed citations

Takashima, Hiroki, Yoshikatsu Koga, Ryo Tsumura, et al.. (2020). Reinforcement of antitumor effect of micelles containing anticancer drugs by binding of an anti-tissue factor antibody without direct cytocidal effects. Journal of Controlled Release. 323. 138–150. 14 indexed citations

Kurasawa, Osamu, Yuya Oguro, T. Miyazaki, et al.. (2017). Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: Synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. Bioorganic & Medicinal Chemistry. 25(7). 2133–2147. 14 indexed citations

Kurasawa, Osamu, Misaki Homma, Yuya Oguro, et al.. (2017). 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Bioorganic & Medicinal Chemistry. 25(14). 3658–3670. 10 indexed citations

Sumi, Hiroyuki, Masakazu Inazuka, Megumi Morimoto, et al.. (2016). An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924). Biochemical and Biophysical Research Communications. 480(3). 380–386. 9 indexed citations

Sumi, Hiroyuki, Masakazu Inazuka, Kentaro Hashimoto, et al.. (2016). T-3256336, a novel and orally available small molecule IAP antagonist, induced tumor cell death via induction of systemic TNF alpha production. Biochemical and Biophysical Research Communications. 479(2). 179–185. 2 indexed citations

Nakamura, Akito, Takeo Arita, Jill Donelan, et al.. (2013). Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. Cancer Research. 73(23). 7043–7055. 92 indexed citations

10.

Hashimoto, Kentaro, Bunnai Saito, Zenyu Shiokawa, et al.. (2013). Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists. Bioorganic & Medicinal Chemistry. 21(18). 5725–5737. 11 indexed citations

11.

Shiokawa, Zenyu, Kentaro Hashimoto, Bunnai Saito, et al.. (2013). Design, synthesis, and biological activities of novel hexahydropyrazino[1,2-a]indole derivatives as potent inhibitors of apoptosis (IAP) proteins antagonists with improved membrane permeability across MDR1 expressing cells. Bioorganic & Medicinal Chemistry. 21(24). 7938–7954. 16 indexed citations

12.

Okaniwa, Masanori, Masaaki Hirose, Takeo Arita, et al.. (2013). Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives. Journal of Medicinal Chemistry. 56(16). 6478–6494. 90 indexed citations

13.

Zhang, Julie, Jerome T. Mettetal, Kazuhide Nakamura, et al.. (2013). Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.. Journal of Clinical Oncology. 31(15_suppl). e13529–e13529. 1 indexed citations

14.

Okaniwa, Masanori, Masaaki Hirose, Takeo Arita, et al.. (2013). Abstract C255: Discovery of TAK-632: A selective kinase inhibitor of pan-RAF with potent antitumor activity against BRAF and NRAS mutant melanomas.. Molecular Cancer Therapeutics. 12(11_Supplement). C255–C255. 1 indexed citations

15.

Sumi, Hiroyuki, Masato Yabuki, Kenichi Iwai, et al.. (2012). Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins. Molecular Cancer Therapeutics. 12(2). 230–240. 12 indexed citations

16.

Okaniwa, Masanori, Takashi Imada, Tomohiro Ohashi, et al.. (2012). Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption. Bioorganic & Medicinal Chemistry. 20(15). 4680–4692. 8 indexed citations

17.

Hirose, Masaaki, Masanori Okaniwa, T. Miyazaki, et al.. (2012). Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. Bioorganic & Medicinal Chemistry. 20(18). 5600–5615. 12 indexed citations

18.

Mizokami, Atsushi, et al.. (2006). Novel HER2 selective tyrosine kinase inhibitor, TAK‐165, inhibits bladder, kidney and androgen‐independent prostate cancer in vitro and in vivo. International Journal of Urology. 13(5). 587–592. 51 indexed citations

19.

Itoh, Fumio, et al.. (2001). ChemInform Abstract: Non‐glutamate Type Pyrrolo[2,3‐d]pyrimidine Antifolates. Part 3. Synthesis and Biological Properties of N^ω‐Masked Ornithine Analogues.. ChemInform. 32(5). 1 indexed citations

20.

Wada, Yasuhiro, et al.. (1991). [Sensitivity test of anti-tumor agents. 2. Application of MTT assay].. PubMed. 18(10). 1587–92. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact